Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
1985
DOI: 10.1016/0022-4731(85)90401-7
|View full text |Cite
|
Sign up to set email alerts
|

RU 38486: A potent antiglucocorticoid in vitro and in vivo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
92
1
3

Year Published

1994
1994
2021
2021

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 172 publications
(101 citation statements)
references
References 24 publications
4
92
1
3
Order By: Relevance
“…2B). In addition, the antiglucocorticoid agent RU 486 [35) almost completely antagonizes the effect of a maximally efficient dose of dexamethasone. Similarly, IL-6-induced transcriptional activity depends on the concentration of the effector with half-maximal and maximal effects observed with 10-20U/ml and 250-500 U/ml, respectively (Fig.…”
Section: Resultsmentioning
confidence: 97%
“…2B). In addition, the antiglucocorticoid agent RU 486 [35) almost completely antagonizes the effect of a maximally efficient dose of dexamethasone. Similarly, IL-6-induced transcriptional activity depends on the concentration of the effector with half-maximal and maximal effects observed with 10-20U/ml and 250-500 U/ml, respectively (Fig.…”
Section: Resultsmentioning
confidence: 97%
“…Commercially available drugs can reduce systemic exposure and toxicity of ingested toxins (Seneca et al 2010). Likewise, the physiological stress response can be suppressed (Gagne et al 1985) or elevated (Muller et al 2009). …”
Section: Future Research Directionsmentioning
confidence: 99%
“…However, all of these potent glucocorticoid analogues still displayed appreciable affinity towards MRs, which hampered the discrimination between MR-and GR-mediated events. In the beginning of the 1980s a new class of selective GR agonists and antagonists became available, which turned out to be very instrumental in quantifying MRs and GRs independently and in studying MR-and GR-mediated effects independently (Philibert and Moguilevski, 1983;Philibert, 1984;Gagne et al, 1985). This new class of analogues includes the synthetic glucocorticoid agonist RU 28362 and the mixed glucocorticoid and progesterone antagonist RU 38486 (see Fig.…”
Section: Mineralocorticoid and Glu~ic~rticoid Receptors In The Brainmentioning
confidence: 99%